Press release
Biliary Tract Cancer Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight
The Biliary Tract Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Biliary Tract Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Biliary Tract Cancer Market.
Some of the key takeaways from the Biliary Tract Cancer Pipeline Report: https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Biliary Tract Cancer treatment therapies with a considerable amount of success over the years.
• Biliary Tract Cancer companies working in the treatment market are Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others, are developing therapies for the Biliary Tract Cancer treatment
• Emerging Biliary Tract Cancer therapies in the different phases of clinical trials are- Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others are expected to have a significant impact on the Biliary Tract Cancer market in the coming years.
• In September 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has received CE IVDR approval for two label extensions of its VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* assay. HER2, a receptor protein expressed in multiple cancers, acts as a predictive biomarker to determine a patient's eligibility for HER2-targeted therapies. The VENTANA HER2 (4B5) test is the first and only companion diagnostic approved to identify HR-positive metastatic breast cancer patients with HER2-ultralow expression. Such patients may qualify for treatment with ENHERTU® (trastuzumab deruxtecan), a specially designed HER2-directed antibody-drug conjugate (ADC) developed by Daiichi Sankyo and co-developed and commercialized with AstraZeneca.
• In April 2025, Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company specializing in oncology and antibody-based therapies, reported that its ongoing Phase 2/3 COMPANION-002 trial evaluating tovecimig (previously CTX-009) in combination with paclitaxel for advanced biliary tract cancer (BTC) met the primary efficacy endpoint with statistically significant top-line results.
• In January 2025, The Phase 3 SWOG S1815 trial (NCT03768414) revealed that adding nab-paclitaxel (Abraxane) to the standard chemotherapy regimen of gemcitabine and cisplatin did not lead to a statistically significant improvement in overall survival (OS) or progression-free survival (PFS) compared to gemcitabine and cisplatin alone in patients with newly diagnosed advanced biliary tract cancer.
• In November 2024, CTX-009 is a bispecific antibody designed to inhibit both Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which play essential roles in angiogenesis and tumor vascularization. Preclinical and early clinical research indicate that targeting these pathways simultaneously enhances anti-tumor efficacy across various solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer. Notably, partial responses have been observed in patients with advanced cancers resistant to standard anti-VEGF therapies. The ongoing COMPANION-002 Phase 2/3 clinical trial is evaluating CTX-009 in combination with paclitaxel versus paclitaxel alone in patients with previously treated, unresectable, advanced, metastatic, or recurrent biliary tract cancers (BTC).
• In April 2024, AstraZeneca has released updated exploratory findings from the TOPAZ-1 Phase III clinical trial, showing that Imfinzi (durvalumab), combined with standard-of-care chemotherapy, provided a long-term overall survival (OS) benefit in patients with advanced biliary tract cancer (BTC) at the three-year mark.
Biliary Tract Cancer Overview
Biliary tract cancer, also known as cholangiocarcinoma, is a type of cancer that arises in the bile ducts, which are the tubes that carry bile (a digestive fluid) from the liver to the gallbladder and small intestine.
Get a Free Sample PDF Report to know more about Biliary Tract Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Biliary Tract Cancer Drugs Under Different Phases of Clinical Development Include:
• Keytruda (pembrolizumab): Merck Sharp & Dohme
• Imfinzi (durvalumab): AstraZeneca
• Futibatinib (TAS-120): Taiho Oncology
• Melphalan: Delcath Systems
• E7090 (tasurgratinib): Eisai
• TT-00420: TransThera Sciences (Nanjing)
• ARQ 087 (Derazantinib): Basilea Pharmaceutica
• Lenvima (lenvatinib): Eisai and Merck & Co
• Zanidatamab: Zymeworks and BeiGene
• XmAb20717: Xencor, Inc.
• Nivolumab + DKN-01: Bristol-Myers Squibb/Leap Therapeutics, Inc.
• CTX-009: Compass Therapeutics
• MEDI5752: AstraZeneca
• Brigimadlin: Boehringer Ingelheim
• ZB131: ZielBio, Inc.
• GQ1001: GeneQuantum Healthcare (Suzhou) Co., Ltd.
• BNT141: BioNTech SE
• SO-C101: SOTIO Biotech
• CT-0508: Carisma Therapeutics Inc
• RAIN-32: Rain Oncology Inc
• AVA6000: Avacta Life Sciences Ltd
• DB-1303: DualityBio Inc.
Biliary Tract Cancer Route of Administration
Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Biliary Tract Cancer Molecule Type
Biliary Tract Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Biliary Tract Cancer Pipeline Therapeutics Assessment
• Biliary Tract Cancer Assessment by Product Type
• Biliary Tract Cancer By Stage and Product Type
• Biliary Tract Cancer Assessment by Route of Administration
• Biliary Tract Cancer By Stage and Route of Administration
• Biliary Tract Cancer Assessment by Molecule Type
• Biliary Tract Cancer by Stage and Molecule Type
DelveInsight's Biliary Tract Cancer Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Biliary Tract Cancer product details are provided in the report. Download the Biliary Tract Cancer pipeline report to learn more about the emerging Biliary Tract Cancer therapies
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Biliary Tract Cancer Therapeutics Market include:
Key companies developing therapies for Biliary Tract Cancer are - Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene, and others.
Biliary Tract Cancer Pipeline Analysis:
The Biliary Tract Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Biliary Tract Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Biliary Tract Cancer Treatment.
• Biliary Tract Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Biliary Tract Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Biliary Tract Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Biliary Tract Cancer drugs and therapies
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Biliary Tract Cancer Pipeline Market Strengths
• The therapeutic landscape in BTCs has expanded considerably in recent years. Combined therapy with chemotherapy, immunotherapy, and modulation of immune checkpoints-mediated signaling pathways are promising strategies.
Biliary Tract Cancer Pipeline Market Opportunities
• Increasing cognizance about different mutations, pathways, and other regimens has changed the focus on curable treatment options with emerging candidates that will lead the growth of the global market.
Scope of Biliary Tract Cancer Pipeline Drug Insight
• Coverage: Global
• Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others
• Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
• Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
• Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biliary Tract Cancer Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight here
News-ID: 4188746 • Views: …
More Releases from DelveInsight Business Research
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
Sjogren's Syndrome Pipeline 2025: Detailed Clinical Trials and FDA-Approved Ther …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Sjogren's Syndrome pipeline constitutes 20+ key companies continuously working towards developing 22+ Sjogren's Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Sjogren's Syndrome Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sjogren's Syndrome Market.
The Sjogren's…
Hyperoxaluria Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evalua …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hyperoxaluria pipeline constitutes 6+ key companies continuously working towards developing 6+ Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Epidermolysis Bullosa Market Growth to Surge During Forecast Period (2024-2034), …
The Epidermolysis Bullosa market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epidermolysis Bullosa pipeline products will significantly revolutionize the Epidermolysis Bullosa market dynamics.
DelveInsight's "Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Epidermolysis Bullosa market trends in the United…
More Releases for Biliary
Global Metal Pancreatic Biliary Stent Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Metal Pancreatic Biliary Stent market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The metal pancreatic biliary stent market is witnessing consistent growth due to the rising prevalence of…
Major Market Share Shift in Biliary Catheters Industry: Advancements In Biliary …
What Is the Forecasted Market Size and Growth Rate for the Biliary Catheters Market?
The market size for biliary catheters has experienced robust growth in recent years. There is an expected growth from $3.42 billion in 2024 to $3.75 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 9.7%. Factors like increased occurrences of biliary tract ailments, the popularity of minimally invasive procedures, a growing aging population, more…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Biliary Stents Market - Unleashing Flow: Empowering Biliary Health with Innovati …
Newark, New Castle, USA - new report, titled Biliary Stents Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Biliary Stents market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Biliary Stents market. The report offers an overview of the market, which…
High Prevalence of Biliary Diseases Across the Globe is Driving the Biliary Sten …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.…
Rise in Surgical Procedures of Biliary Diseases is Expected to Boost the Biliary …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.…
